United Therapeutics Reports Q3 2026 Revenue Growth Amid Increased R&D Spending
United Therapeutics (UTHR) reported third-quarter 2026 revenues of $832.5 million, a 4% year-over-year increase driven by strong performance from Tyvaso DPI and Orenitram. Despite the revenue growth, net income fell 24% to $258.6 million, primarily due to a significant 119% surge in research and development expenses following the acquisition of Thymmune Therapeutics and investments in organ alternative projects. The company is navigating several regulatory and operational shifts, including delaying its Soft Mist Inhaler NDA submission to 2027 and managing an API supplier compliance issue. On a positive note, October referrals reached record highs, and the Board approved a new $2 billion share repurchase program following the completion of a previous authorization.
Tickers: $UTHR
Topics: net income decrease product sales performance R&D expenditure revenue growth